Objectives: Previously, web-based tools for cross-sectional antimicrobial point prevalence surveys (PPSs) have been used in adults to develop indicators of quality improvement. We aimed to determine the feasibility of developing similar quality indicators of improved antimicrobial prescribing focusing specifically on hospitalized neonates and children worldwide.
Introduction
Antimicrobial resistance is a major public health problem and continuing progress in the treatment of many infections is threatened by the growing resistance of pathogens to antimicrobial agents. 1 Judicious use of antibiotics is essential to slow the emergence of antibiotic resistance in bacteria and extend the useful lifetime of effective antibiotics. 2 The 2011 European Commission Action Plan against the rising threats from antimicrobial resistance emphasized the importance of surveillance data with regard to antimicrobial use and resistance at local and national levels and the role of antibiotic stewardship. 3 Also, President Obama of the USA has recently increased efforts to combat and prevent antibiotic resistance, among which is the core aim of improving the quality of antibiotic prescribing. 4, 5 Access to standardized and validated antibiotic surveillance data is essential to assess the appropriateness of antimicrobial prescriptions and to set and monitor outcomes of interventions. There is as yet no consensus regarding the use of indicators to monitor trends of antibiotic use in hospitals. 6 The European Surveillance of Antimicrobial Consumption (ESAC) project developed and validated a web-based point prevalence survey (PPS) tool to evaluate hospital antimicrobial prescribing rates at local and national level. The ESAC-PPS identified inappropriate use linked to specific agents or specialties, proposed quality indicators of prescribing practices and identified targets to improve antimicrobial prescribing. 7 -9 The ESAC-PPS tool was used to set quantitative targets for improved antibiotic prescribing in adults and to measure the effectiveness of interventions to reach these targets through repeated PPSs. 10, 11 Currently, no comparable detailed information on antibiotic use in hospitalized neonates and children is available. Longitudinal surveys of antimicrobial use in neonates and children are in part lacking because there is no consensus on the indicators that should be used to monitor trends of antibiotic use. PPS tools were not specifically designed for capturing antimicrobial prescribing data in this population. As part of the Antibiotic Resistance and Prescribing in European Children (ARPEC) project, 12 the ESAC-PPS tool was specifically adapted to survey antimicrobial use in hospitalized neonates and children (ARPEC-PPS; work package 5). The feasibility of carrying out the ARPEC-PPS method in a large number of hospitals was piloted in 73 hospitals from 23 different countries in 2011. 13 After a successful pilot study, this survey was subsequently rolled out as a global ARPEC-PPS in a very large set of hospitalized neonates and children worldwide.
The study aimed to describe antibiotic prescribing practices among hospitalized neonates and children worldwide and to determine the feasibility of adapting existing adult quality indicators of optimal prescribing to neonates and children.
Materials and methods

Ethics
This study was a completely anonymized audit of current antimicrobial prescribing practices. No unique identifiers were entered into the database. Every patient record was given a unique non-identifiable survey number, which was automatically generated by a computer program specifically designed for anonymous data entry. Formal ethics approval for this study depended on the country and was taken care of by each participating hospital if required.
Countries and hospitals
Paediatric infectious disease specialists, clinical microbiologists and pharmacists, and other interested healthcare professionals from established networks such as the European Society of Paediatric Infectious Diseases 14 and Global Research in Paediatrics, 15 were invited to participate in this worldwide ARPEC-PPS conducted in October-November 2012. We collected data from 226 hospitals from 41 countries belonging to the six United Nations (UN) regions (Africa, Asia, Oceania, Latin America, North America and Europe). 16 For Europe, four geographical UN sub-regions were defined: 16 17 Four main paediatric ward types were defined: general paediatric medical wards (GPMWs); paediatric surgical wards (PSWs); paediatric intensive care units (PICUs); and specialized paediatric medical wards (SPMWs). The last type included haematology/oncology special paediatric medical wards (HO-SPMWs), cardiology wards (C-SPMWs), transplant wards (bone marrow transplant/solid) (T-SPMWs) and all others (other-SPMWs). Neonatal wards included three aggregated neonatal intensive care unit (NICU) levels providing special care (NICU level 1), high-dependency care to low birth weight neonates (NICU level 2) or tertiary referral care to very low birth weight neonates (NICU level 3), and a general neonatal medical ward (GNMW). 18 
Data collection
As described in full detail elsewhere, 13 participants were asked to conduct a 1 day cross-sectional PPS during which all paediatric and neonatal wards had to be audited once within a fixed period of time. The PPS included all neonates (,30 days) and children ,18 years old present in the ward at 8:00 am at least since midnight on the day of the survey. Data collection was based on the standardized ESAC-PPS protocol. For each patient receiving at least one antimicrobial, mandatory data included prescribed antimicrobial agent (dose per administration, number of doses per day and route of administration), age and gender, indication for treatment (community-acquired, hospital-acquired, surgical prophylaxis and medical prophylaxis), reason for treatment according to a predefined list, speciality (medicine, surgery or intensive care) and whether the reasons for treatment were documented in the patient notes. Information on surgical prophylaxis was captured for the previous 24 h, indicating 1 dose, 1 day or .1 day. The ESAC-PPS protocol was further adapted for the purpose of collecting data on children and neonates. Additional mandatory variables included: underlying diagnosis according to predefined lists of common medical and surgical conditions in children and neonates; whether the treatment was targeted (based upon microbiological culture and sensitivity testing) or empirical; and current weight and ventilation status. For premature neonates, birth weight and gestational age were also collected. Denominators included the total number of patients present on the ward at 8:00 am and the total number of beds by the predefined six different paediatric and four neonatal department types.
Drugs were classified according to the standardized and internationally recognized WHO Anatomical Therapeutic Chemical (ATC) classification system classifying drugs according to their main therapeutic use. 19 Antibiotics were grouped into antibacterials for systemic use (ATC J01), oral metronidazole (ATC P01AB01), intestinal anti-infectives (oral antibiotics vancomycin, paromomycin and colistin, ATC A07AA) and antibiotic drugs for the treatment of tuberculosis (rifampicin, ATC J04AB02). Antimycotics for systemic use (ATC J02) were merged with antifungals classified under the intestinal anti-infectives (ATC A07AA: oral nystatin, amphotericin B, miconazole). We further collected data on antivirals for systemic use (ATC J05), nitroimidazole derivatives (ATC P01AB) and antimalarials (ATC P01B).
Data collection was performed using paper forms, after which data were entered into a central database using a web-based application for data entry, validation and reporting. All data were mandatorily entered online. The software was designed to avoid missing data (e.g. it was not possible to enter incomplete patient and denominator files online and complete the submission). The data validation procedure involved extra checks on erroneous data entry, e.g. extremely high antibiotic prevalence rates, possibly involving wrong denominators, and extremely high dosing. All data were completely anonymously entered into the database and safeguarded at the University of Antwerp, Belgium. A helpdesk as well as a frequently asked question list were available in support of the participants. Participation was exclusively on a voluntary basis and the numbers of hospitals and patients were not intended to be representative of a country or region. Depending on the countries' legal requirements, hospitals had to comply with local ethics approval. A data privacy excerpt document was made available for this purpose. Informed consent was not needed because the survey did not require direct involvement or contact with the patient, treatment or other intervention.
Data analysis
For this paper, antimicrobial use is reported as the number of treated patients and the number of therapies. Therapy was defined as the use of one substance in one route of administration. Antimicrobial prescribing rates and the derived potential quality indicators (Table 1) are expressed as percentages (proportional use), means and/or ranges aggregated at UN regional level, 16 by ward type, by indication (therapeutic or prophylactic antibiotic prescribing) or according to age category (children aged .1 month and neonates aged ,30 days). We also ranked the number of antibacterials for systemic use (ATC code J01) accounting for 90% and 75% of (antibiotic) drug utilization (DU90% and DU75%, respectively). Overall, 56% of treated children were males (range, from 49% in Africa to 59% in Latin America). Among antimicrobial prescriptions for children, antibiotics represented 85.7% (n¼7987), followed by antimycotics (9.6%, n¼891) and antivirals (4.7%, n¼ 446). Among antimicrobial prescriptions for neonates, antibiotics represented 89.2% (n¼2298), followed by antimycotics (8.8%, n¼227) and antivirals (1.9%, n¼50). Figure 1 for a subset of the classification categories) were recorded worldwide. Figure 1 reports the most commonly prescribed antibiotics among children. In all regions except North America, b-lactams made up Versporten et al.
Results
General overview
Potential indicators of antibiotic prescribing
Antibiotic drug utilization at regional level in children
more than half of all antibiotic prescriptions. Third-generation cephalosporins were most frequently prescribed in Eastern Europe (35.7%) and Asia (28.6%), fourth-generation cephalosporins (cefepime) in North America (7.8%) and carbapenems in Latin America (13.3%). A considerable amount of narrow-spectrum antibiotics was prescribed in Africa and Northern Europe (e.g. b-lactamase-sensitive penicillins, 11.0% and 4.3%, respectively) and Australia (e.g. first-generation cephalosporins, 9.6%). Table 3 reports the specific antibiotics prescribed to children by UN region, ranked at overall DU90%. In total, 77 different systemic antibiotic substances (ATC J01) were administered to children. Ceftriaxone (8.5% of total use of antibiotics) ranked first in Eastern Europe, Asia and Southern Europe (31.3%, 13.0% and 9.8%, respectively). In Western Europe and Australia, cefotaxime was more popular than ceftriaxone (4.8% and 5.6%, respectively), while cefepime was more commonly prescribed in North America (7.8%). The second most prescribed antibiotic was sulfamethoxazole/trimethoprim (7.2% of total antibiotic use), ranking first in Western Europe (11.4%), North America (11.2%) and Australia (10.0%). Vancomycin ranked second in Latin America (12.9%), North America (10.6%) and Asia (8.5%). Meropenem ranked first in Latin America (13.1%). Figure 2 shows the most prevalently prescribed antibiotics among neonates. Aminoglycosides in combination with either ampicillin/ amoxicillin (Western and Southern Europe, Asia, Latin America and North America) or benzylpenicillin (Northern Europe, Africa and Australia) were by far the most frequently used regimens. Table 4 shows the antibiotics prescribed to neonates by UN region, ranked at overall DU90%. In total, 43 different systemic antibiotic substances were prescribed to neonates worldwide. Gentamicin (23.6% of total antibiotic use) ranked first in 
Antibiotic drug utilization at regional level in neonates
Antibiotic prescribing by indication
The most frequently recorded reason to treat children was a bacterial lower respiratory tract infection (18.7%) and that to treat neonates was sepsis (36.4%) (see Table 5 for the top 10 reasons for antibiotic treatment in children and neonates). Tables 6 and 7 compare therapeutic (community-acquired versus hospital-acquired; empirical versus targeted treatment) and prophylactic prescribing in children and neonates: 75.3% of antibiotics were prescribed therapeutically (75.4% in children and 74.9% in neonates) and 24.7% prophylactically (14.8% for medical and 9.8% for surgical prophylaxis in children and 19.5% for medical and 5.6% for surgical prophylaxis in neonates). Global Point Prevalence Survey in hospitalized children in 2012 27 .9% in North America). The most commonly prescribed antibiotics for CAIs were third-generation cephalosporins (mainly ceftriaxone) in Asia, Latin America and Europe (32.8%, 23.5% and 18.7% of total antibiotic use for treatment of CAIs, respectively) followed by aminoglycosides (mainly gentamicin) in Africa, Australia and Europe (26.6%, 17.6% and 14.6%, respectively), broad-spectrum penicillins (mainly amoxicillin) in North America, Europe and Australia (14.5%), combinations of penicillins with an enzyme inhibitor (mainly co-amoxiclav) in Europe, North America and Australia (14.2%, 11.9% and 10.0%, respectively), narrowspectrum penicillins (mainly benzylpenicillin) in Africa (16.5%), and clindamycin in Latin and North America (12.0% and 10.2%, respectively).
Prophylactic prescribing Medical prophylactic prescribing accounted for 64.3% of all prophylactic antibiotic prescribing, ranging from 55.8% in Asia to 82.9% in Africa. Overall, antibiotics were more commonly prescribed for medical prophylaxis in neonates (77.8%; range, from 28.6% in Africa to 89.1% in Australia) compared with children (60.3%; range, from 42.9% in Asia to 96.4% in Africa) (Tables 6 and 7 ). Many different antibiotics were prescribed for medical prophylactic use, with sulfamethoxazole/ trimethoprim dominating in Africa, North America, Australia and Europe (79.3%, 36.2%, 34.2% and 30.5% of total medical prophylactic prescribing, respectively) and ampicillin in Latin America and Asia (21.5% and 15.9%, respectively).
Surgical prophylactic prescribing accounted for 39.7% of all prophylactic antibiotic prescribing in children, compared with 22.2% in neonates (Tables 6 and 7) . Most antibiotics for surgical prophylactic use were first-generation cephalosporins, mainly cefazolin in North America and Australia (61.1% and 47.0% of total surgical prophylactic prescribing, respectively) and cefalotin in Latin America (27.5%), followed by third-generation cephalosporins (mainly ceftriaxone) in Asia and Europe (25.6% and 14.6%, respectively), second-generation cephalosporins (mainly cefuroxime) (17.5%) or combinations of penicillins with enzyme inhibitors (mainly co-amoxiclav) in Europe (16.6%). Prolonged surgical prophylaxis (.1 day) was very common in all regions, ranging from 78% in Europe to 84% in Latin America.
Discussion
This global ARPEC-PPS for the first known time explored the feasibility of producing qualitative indicators to uniformly assess antimicrobial prescribing, to identify key areas of poor practice and to propose benchmarks for improved antibiotic prescribing among hospitalized neonates and children worldwide.
Overall, we found less regional difference in antibiotic prescribing among hospitalized neonates than among children. The dominance of gentamicin used in combination with benzylpenicillin or ampicillin across all regions was very striking, and explains the high proportion of antibiotics used in combination among neonates (around 70%). Remarkably high use of amikacin was noted in neonates admitted to Western European, Southern European, Asian and Latin American hospitals, and, worryingly, meropenem was widely prescribed to Asian neonates.
In contrast, we observed striking regional differences in antibiotic prescribing among hospitalized children. A high proportion 
Global Point Prevalence Survey in hospitalized children in 2012
1111 JAC of African, Australian, Western European and Northern European children continued to receive older narrow-spectrum antibiotics, mainly benzylpenicillin, sulfamethoxazole/trimethoprim, amoxicillin and gentamicin. Africa was characterized by considerably high use of gentamicin, often in combination with benzylpenicillin. Eastern European, Southern European, Asian, North American and Latin American children received considerably more broadspectrum antibiotics, mainly third-generation cephalosporins, cefepime and meropenem. The prevalence of broad-spectrum agent use is an important quality indicator in children. The high use seen here may be partially explained by the remarkably high antibiotic prescribing rates for HAIs as an indication, e.g. in Latin America (49.9%), Asia (34.9%) and North America (33.7%), again with high proportions of meropenem, ceftriaxone and cefepime use. The striking finding of the high number of antibiotics prescribed for HAIs in neonates, reaching 68% of all therapeutic prescribing in Latin America, requires further investigation. In Europe we observed slightly lower prevalence rates of antimicrobials prescribed for an HAI (28.9%), comparable to the ESAC 2009-PPS (adults and children, 30.7%) 8 and the ECDC 2010-PPS (paediatric wards, 30.3%).
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High proportions of broad-spectrum antibiotic use could be explained by regionally high rates of ESBL-producing or carbapenemresistant Gram-negative organisms. Surveillance programmes in Latin America in adults and children have demonstrated an increasing trend of resistance to extended-spectrum cephalosporins with high prevalence of ESBL-producing Escherichia coli and Klebsiella spp. and carbapenem-resistant Klebsiella spp. 21, 22 Similarly, in Asia the burden of antimicrobial resistance is now very high. 23 It is unclear whether, in the surveyed children, this high level of use of broadspectrum antibiotics was indeed justified by local resistance patterns, due to the absence of linked local neonatal and paediatric antimicrobial resistance data. However, the high level of empirical antibiotic use may indicate that at least a proportion of this prescribing may be inappropriate. Such inappropriate use was found by Levy et al. 24 in PICUs and paediatric wards, which the authors attributed to failure to discontinue or de-escalate therapy. Even in resource-limited settings, where de-escalation may be less commonly considered and where bacteriological cultures are much less frequently performed, successful de-escalation of carbapenems has been reported. 25 Therefore, to limit microbial selection pressure, de-escalation upon culture results should be implemented whenever possible. 26 We identified several other potential indicators to assess antimicrobial prescribing that could be used to set benchmarks for quality improvement of antibiotic use in children and neonates. The simple prevalence of antibiotic use by ward, by hospital or at national level could be used as a quality indicator if prescription rates are much higher than in other comparators as part of a benchmarking programme. The worldwide prevalence rate of antimicrobial prescribing among children's wards was 36.7%, with high rates observed in PICUs (61%) and on surgical wards (35%), which were twice as high compared with the ESAC 2009-PPS (PICUs, 30%; child surgical wards, 16%). 9 Setting crude prevalence quantitative targets at the hospital level is very difficult because antibiotic use depends on many variables, including patient case-mix, type of hospital, proportion of HAIs and prevalence of resistance. For instance, 80% of the centres taking part in this ARPEC-PPS were tertiary care hospitals, with several specialized stand-alone paediatric hospitals. Therefore, we collected data from a high number of Versporten et al. Sixty-eight antibiotics were recorded with unknown indication. Global Point Prevalence Survey in hospitalized children in 2012 children receiving specialized care admitted to, e.g. haematology/ oncology and transplant wards as well as very low birth weight neonates who were admitted to level 3 NICUs. This could explain the high overall antibiotic prescribing rates. There is a need to further develop the data collection with more hospitals, reducing the selection bias and stratifying for hospital type and case-mix to develop more appropriate benchmarking standards. The early switch from parenteral to oral therapy is another quality indicator, due to its many advantages, such as decreased risk of catheter-related infections, reduced costs and the possibility of early discharge from hospital. 27, 28 However, it is not known to what extent different antibiotic administration routes have an impact on antimicrobial resistance. 29 Parenteral administration among children was more frequent in Asia, Latin America and Europe (88%, 81% and 67%, respectively) compared with adults in Europe in the ESAC-PPS (60%). 8 The concept of early switching from parenteral to oral therapy seems uncommon among children 28 and could be explained by more limited options for oral broad-spectrum antibacterial equivalents with appropriate formulations, class and potency and the challenges of oral administration of medications in young children in general. 30 A parenteral-to-oral switch-over programme in line with available guidance can, however, be introduced into clinical practice 28 and should be supported by collecting information for particular indications in children. 31 A further key quality indicator is documentation of the reason for prescription in the medical notes of the patient, which was slightly less in European children (76%) than in European adults (80%), 8 but considerably lower in Latin America (52%). Good documentation of the indication in the patient chart ensures communication of diagnosis and treatment among clinicians, pharmacists and other healthcare providers, and allows subsequent prescription review and interventions such as de-escalation and stopping of antimicrobial treatment. This ESAC-PPS indicator was used to set a benchmark of .95% in Scottish hospitals.
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Another potential quality indicator is the administration of antibiotics for surgical prophylaxis. We proposed an international benchmark of 100% for surgical prophylaxis prescriptions being administered ,24 h, 7 because the duration of surgical prophylaxis should not exceed a 24 h perioperative period unless exceptional cases. 32 Therefore, the excessively lengthy surgical prophylaxis for .24 h observed in many hospitals participating in this survey (up to 84% in Latin America hospitals) is not acceptable. Moreover, in these hospitals we observed high broad-spectrum surgical prophylactic prescribing, mainly ceftriaxone, which could be explained by the concern about increasing resistance to first-and secondgeneration cephalosporins among Gram-negative isolates. In other parts of the world, mostly first-and second-generation cephalosporins were administered. Equally concerning is the high proportion of antibiotics prescribed for medical prophylaxis in all regions except Africa, including high levels of neonatal medical prophylaxis. Indeed, medical prophylaxis was the second most common reason for antibiotic treatment in children, accounting for 15% of all prescriptions. Whether this is an area for quality improvement needs to be further explored with more detailed evaluation of patterns of prophylactic antibiotic use and their relation to available evidence.
Study strengths and limitations
The strength of our study lies in the uniformity of data collection, the simplicity of the protocol and data collection templates (less time consuming); and the assurance of data quality (data completeness and validation process) as described in Versporten et al. 13 The limitations of this study are inherent to the epidemiological method of a cross-sectional survey. 13 Additionally, as mentioned above, the recruitment of hospitals, mainly done through existing paediatric or other networks, involving a high number of highly specialized or referral hospitals, will have induced selection bias and may partially explain the high antimicrobial prevalence rates observed. This indicator is strongly associated with patient characteristics. However, it does not necessarily explain some worrying findings with respect to quality indicators, such as the low frequency of documenting the reason for treatment in the medical files or prolonged antibiotic prescribing for surgical prophylaxis. These quality indicators should be met independently of institutional characteristics. Finally, we do not suspect social desirability bias. We dealt with highly motivated infectious disease specialists or other, related specialists who often perform a supervisory function at hospital level. We also clearly communicated in different ways that they needed to complete the forms with information, which was written down in medical or other files, without discussing the appropriateness of the prescribed antimicrobial.
The 2015 WHO global action plan on antimicrobial resistance proposes collection and reporting of data on the use of antimicrobial agents so that trends can be monitored and the impact of action plans assessed, but does not specifically mention the difficulties of data collection and analysis in children. 33 Our ARPEC-PSS tool constituted a simple method to collect antimicrobial prescribing data electronically. The uniformity of data collection together with the implemented online quality assurance improves the validity of the data we collected worldwide. This is of great value to public health nationally and globally as these methods can be implemented and repeated regionally in the future. 34 It can also provide meaningful educational feedback to prescribers, which could have a significant effect on prescribing practices. We have now identified several measurable quality indicators that could be used to set benchmarks for antibiotic prescribing in neonates and children. The next step is to implement feasible quality targets through repeated PPSs (e.g. quarterly) on a sample of patients or wards within the same hospitals. This will allow the future prospective assessment of intervention plans aimed at improving the quality of antibiotic prescribing.
